JP2000511424A - ラクトフェリン変異体およびその使用 - Google Patents

ラクトフェリン変異体およびその使用

Info

Publication number
JP2000511424A
JP2000511424A JP09543045A JP54304597A JP2000511424A JP 2000511424 A JP2000511424 A JP 2000511424A JP 09543045 A JP09543045 A JP 09543045A JP 54304597 A JP54304597 A JP 54304597A JP 2000511424 A JP2000511424 A JP 2000511424A
Authority
JP
Japan
Prior art keywords
lactoferrin
iron
vector
binding
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP09543045A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000511424A5 (enExample
Inventor
コネリー，オーラ・エム
ウォード，ポーリーン・ピー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of JP2000511424A publication Critical patent/JP2000511424A/ja
Publication of JP2000511424A5 publication Critical patent/JP2000511424A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP09543045A 1996-05-31 1997-06-02 ラクトフェリン変異体およびその使用 Ceased JP2000511424A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1874796P 1996-05-31 1996-05-31
US60/018,747 1996-05-31
US08/866,544 1997-05-30
US08/866,544 US6111081A (en) 1996-05-31 1997-05-30 Lactoferrin variants and uses thereof
PCT/US1997/009531 WO1997045136A1 (en) 1996-05-31 1997-06-02 Lactoferrin variants and uses thereof

Publications (2)

Publication Number Publication Date
JP2000511424A true JP2000511424A (ja) 2000-09-05
JP2000511424A5 JP2000511424A5 (enExample) 2005-01-13

Family

ID=26691448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP09543045A Ceased JP2000511424A (ja) 1996-05-31 1997-06-02 ラクトフェリン変異体およびその使用

Country Status (12)

Country Link
US (1) US6111081A (enExample)
EP (1) EP0959898A4 (enExample)
JP (1) JP2000511424A (enExample)
KR (1) KR20000016159A (enExample)
AU (1) AU707476B2 (enExample)
CA (1) CA2256453A1 (enExample)
DE (1) DE959898T1 (enExample)
ES (1) ES2140362T1 (enExample)
GR (1) GR990300043T1 (enExample)
IL (1) IL127319A (enExample)
NZ (1) NZ333215A (enExample)
WO (1) WO1997045136A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013162050A1 (ja) * 2012-04-23 2013-10-31 株式会社Ｎｒｌファーマ ラクトフェリン融合タンパク質及びその製造方法
CN104245739B (zh) * 2012-04-23 2018-06-01 Nrl制药股份有限公司 乳铁蛋白融合蛋白及其制备方法
US11041014B2 (en) 2016-10-28 2021-06-22 S & K Biopharma, Inc. Lactoferrin/albumin fusion protein and production method therefor

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94183A (en) * 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
JP2002515893A (ja) * 1997-02-03 2002-05-28 ファーミング インテレクチュアル プロパティ ビーブイ ヒトラクトフェリンおよびその改変体の有用な特性
ATE297755T1 (de) * 1997-04-10 2005-07-15 Agennix Inc Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
US6399570B1 (en) 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
JP3668241B2 (ja) * 2001-12-28 2005-07-06 株式会社Ｎｒｌファーマ 脂質代謝改善用組成物
US20030213007A1 (en) * 2002-03-27 2003-11-13 Slattery Charles Wilbur Human milk produced by human mammary tissue implanted in non-human host animals and uses thereof
EP2286827A1 (en) 2002-05-10 2011-02-23 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
AU2003233583A1 (en) * 2002-05-24 2003-12-12 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
DK2298338T3 (da) * 2002-09-16 2012-09-24 Agennix Inc Lactoferrin-sammensætninger og fremgangsmåder til behandling af hudsår
JP4795021B2 (ja) * 2002-12-06 2011-10-19 エイジェニックス インコーポレイテッド 敗血症治療における経口用ラクトフェリン
US7592306B2 (en) * 2002-12-10 2009-09-22 Agennix, Inc. Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
WO2004060392A1 (en) * 2002-12-20 2004-07-22 Ventria Bioscience Lactoferrin protein with iron for treating iron deficiency and anemia
AU2004289170B2 (en) * 2003-06-06 2009-12-17 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
US20040259770A1 (en) * 2003-06-19 2004-12-23 Rush University Medical Center Method for determining leukocyte activation
US20050075277A1 (en) * 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
WO2006047744A2 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
NZ555163A (en) 2007-05-14 2010-05-28 Fonterra Co Operative Group Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
RU2340674C1 (ru) * 2007-06-01 2008-12-10 Борис Савельевич Народицкий Способ получения рекомбинантного лактоферрина человека
WO2020096672A1 (en) 2018-11-09 2020-05-14 The Wistar Institute Of Anatomy And Biology Use of lactoferrin for generating myeloid-derived suppressor cells

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5186117A (en) * 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
GB1575343A (en) * 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
US4529561A (en) * 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
IN150740B (enExample) * 1978-11-24 1982-12-04 Hoffmann La Roche
GB2046092B (en) * 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4452747A (en) * 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4652639A (en) * 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4740461A (en) * 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4710465A (en) * 1984-04-19 1987-12-01 Yale University Junction-fragment DNA probes and probe clusters
US5008050A (en) * 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
LU85479A1 (fr) * 1984-07-25 1986-02-12 Oleofina Sa Compositions antibacteriennes de nourriture pour animaux et procede pour les preparer
US4921706A (en) * 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
JPS61145200A (ja) * 1984-12-19 1986-07-02 Snow Brand Milk Prod Co Ltd ウシラクトフェリンの分離精製法
US4886747A (en) * 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
AU5912586A (en) * 1985-06-20 1986-12-24 Salk Institute Biotechnology/Industrial Associates, Inc., The Alpha-factor leader peptide-facilitated secretion from transformed s cerevisiae
FR2583676B1 (fr) * 1985-06-24 1988-03-25 Induplast Sa Procede et appareils d'extrusion de structures alveolaires en matiere thermoplastique et structures ainsi obtenues
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4965190A (en) * 1986-07-31 1990-10-23 Howard Hughes Medical Institute Methods for the identification of mutations in the human phenylalanine hydroxylase gene using DNA probes
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5009956A (en) * 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
US5019508A (en) * 1987-08-27 1991-05-28 Biotechnology Research Partners, Ltd. Synovial phospholipases
DE3886221T3 (de) * 1987-09-04 2000-12-21 Novo Nordisk A/S, Bagsvaerd VERFAHREN ZUR HERSTELLUNG VON PROTEINPRODUKTEN IN -i(ASPERGILLUS) UND PROMOTOREN ZUR VERWENDUNG IN -i(ASPERGILLUS).
US5081227A (en) * 1988-03-04 1992-01-14 La Jolla Cancer Research Foundation Germ cell alkaline phosphatase
US4927637A (en) * 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
US4944948A (en) * 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
US5571691A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5571697A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US5155037A (en) * 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
IL95697A0 (en) * 1989-09-28 1991-06-30 Granada Biosciences Inc Cdna sequence for porcine lactoferrin protein
AU7453391A (en) * 1990-03-08 1991-10-10 Ferrodynamics, Inc. Genetically engineered human lactoferrin
JP2818056B2 (ja) * 1990-09-07 1998-10-30 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
NZ245713A (en) * 1992-02-10 1994-12-22 Novopharm Ltd Production of the antibiotic lovastatin from genetically engineered aspergillus strains
ZA932568B (en) * 1992-04-24 1993-11-12 Baylor College Midecine A Non Production of recombinant human lactoferrin
US5571619A (en) * 1994-05-24 1996-11-05 Exxon Chemical Patents, Inc. Fibers and oriented films of polypropylene higher α-olefin copolymers

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013162050A1 (ja) * 2012-04-23 2013-10-31 株式会社Ｎｒｌファーマ ラクトフェリン融合タンパク質及びその製造方法
CN104245739A (zh) * 2012-04-23 2014-12-24 Nrl制药股份有限公司 乳铁蛋白融合蛋白及其制备方法
JPWO2013162050A1 (ja) * 2012-04-23 2015-12-24 株式会社Ｎｒｌファーマ ラクトフェリン融合タンパク質及びその製造方法
JP2016117717A (ja) * 2012-04-23 2016-06-30 株式会社Ｎｒｌファーマ ラクトフェリン融合タンパク質及びその製造方法
US9809641B2 (en) 2012-04-23 2017-11-07 Nrl Pharma, Inc. Lactoferrin fusion protein and method for preparation thereof
CN104245739B (zh) * 2012-04-23 2018-06-01 Nrl制药股份有限公司 乳铁蛋白融合蛋白及其制备方法
US10562959B2 (en) 2012-04-23 2020-02-18 Nrl Pharma, Inc. Lactoferrin fusion protein and method for preparation thereof
US11041014B2 (en) 2016-10-28 2021-06-22 S & K Biopharma, Inc. Lactoferrin/albumin fusion protein and production method therefor

Also Published As

Publication number Publication date
AU3227197A (en) 1998-01-05
US6111081A (en) 2000-08-29
NZ333215A (en) 2000-05-26
KR20000016159A (ko) 2000-03-25
GR990300043T1 (en) 2000-01-31
ES2140362T1 (es) 2000-03-01
CA2256453A1 (en) 1997-12-04
EP0959898A4 (en) 2002-08-14
WO1997045136A1 (en) 1997-12-04
AU707476B2 (en) 1999-07-08
EP0959898A1 (en) 1999-12-01
DE959898T1 (de) 2000-05-04
IL127319A0 (en) 1999-09-22
IL127319A (en) 2004-08-31

Similar Documents

Publication Publication Date Title
AU707476B2 (en) Lactoferrin variants and uses thereof
TW458984B (en) Novel mutant hIL-4 proteins as antagonists or partial agonists of human interleukin 4
WO1997045136A9 (en) Lactoferrin variants and uses thereof
JPH08511167A (ja) ケモカインの生物学的活性の強化法
CN104710535B (zh) 重组人g-csf二聚体及其在治疗神经系统疾病中的用途
JPS62174026A (ja) 白血球減少症治療剤
JP7830450B2 (ja) 修飾されたｉｌ－２分子及びその用途
JP2026515377A (ja) 神経系修復のためのタンパク質チロシンホスファターゼ楔ドメインペプチドダイマー
WO2023151594A1 (en) A composition comprising gip receptor agonists and glp-1 receptor agonists and use thereof
JP2011503137A (ja) 新規のアルギニン置換ペプチド及びその使用
JP2012511309A (ja) Ｅｃ−ｓｏｄのカルボキシル末端のアポプチンタンパク質導入ドメインの融合蛋白質
WO2025133189A1 (en) Sleep promoting peptides and the use thereof
US7585647B2 (en) Nucleic acid encoding recombinant interferon
WO1999055864A1 (fr) Nouveau polypeptide, adnc le codant et son utilisation
WO2000008056A1 (fr) NOUVEAU POLYPEPTIDE, ADNc LE CODANT ET SON UTILISATION
CN119874872B (zh) 一种mita铰链区突变多肽及其在自身免疫性疾病中的应用
MX2010010795A (es) Uso de defensinas contra meningitis.
CN120988072A (zh) 多肽pn-vw22及其应用
MXPA98010080A (en) Variants of lactoferrina and uses of the mi
CN121779512A (zh) 具有抗马拉色菌活性的多肽及其在改善脂溢性皮炎中的用途
WO2025049019A1 (en) Variants of human programmed cell death protein (pd-1)
HK1021333A (en) Lactoferrin variants and uses thereof
CN105237641A (zh) Vegf-b和vegf-b融合蛋白及其应用
WO2023280144A1 (zh) 一种融合蛋白及其医药用途
SK1652011U1 (sk) Bioactive regenerative mixture for producing nutritional preparation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061121

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20070413

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070522